Anago Inc. v. Tecnol Medical Products, Inc.

792 F. Supp. 514, 1991 U.S. Dist. LEXIS 20114, 1992 WL 89167
CourtDistrict Court, N.D. Texas
DecidedFebruary 26, 1992
DocketCiv. A. 3-92-250-H
StatusPublished
Cited by6 cases

This text of 792 F. Supp. 514 (Anago Inc. v. Tecnol Medical Products, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Anago Inc. v. Tecnol Medical Products, Inc., 792 F. Supp. 514, 1991 U.S. Dist. LEXIS 20114, 1992 WL 89167 (N.D. Tex. 1992).

Opinion

MEMORANDUM OPINION AND ORDER

SANDERS, Chief Judge.

Plaintiff Anago Incorporated (“Anago”) seeks a preliminary injunction enjoining Defendant Tecnol Medical Products (“Tec-nol”) from further pursuing its attempt to acquire control over Anago and effectuate a merger between the two companies. An-ago contends that Tecnol’s activities violate Section 7 of the Clayton Act, 15 U.S.C. § 18, which prohibits mergers that substantially lessen competition, and Section 14(e) of the Securities Exchange Act of 1934, 15 U.S.C. § 78n(e), as amended (the “Williams Act”), which prohibits certain deceptive or manipulative practices in connection with a tender offer. 1

The Court held an evidentiary hearing on the Application for Preliminary Injunction on February 14, 1992. Based on the testimony and facts presented at the hearing, as well as the affidavits, depositions, arguments, and briefs presented by counsel, the Court concludes that the Plaintiff has not demonstrated a threat of “antitrust injury” sufficient for issuance of a preliminary injunction under Section 16 of the Clayton Act. Nor will a preliminary injunction issue on Plaintiff’s securities claim. The Court concludes that Defendant’s attempt to acquire control over Anago did not constitute a “tender offer” within the meaning of Section 14 of the Williams Act, and thus, the Plaintiff is not likely to prevail on the merits.

I. BACKGROUND

Anago and Tecnol design, manufacture and market disposable operating room apparel and certain related disposable medical specialty products. The disposable medical products market, by all accounts, is highly competitive and dominated by a relatively small number of companies. Although An-ago and Tecnol do not make all of the same products, they are direct competitors with respect to several of their most important products — surgical face masks, isolation masks, and ice filled insulated ice packs. The two companies do not sell to exactly the same markets, but both focus their marketing strategy on hospitals within the United States. Together, they control a large percentage of the market for surgical face masks, isolation masks, and insulated ice packs sold to U.S. hospitals.- Both Ana-go and Tecnol are based in Fort Worth, Texas.

Incorporated in 1978, Anago is the smaller corporation, privately held, with approximately eighty shareholders and 700 employees. Anago prides itself as a “price maverick,” operating on a smaller margin of profit than its competitors. Since its formation, Anago’s net sales and market share have steadily increased, particularly with respect to its face mask and insulated ice pack product lines. The growth in business is largely attributable to Anago’s willingness and ability to undercut the prices of its competitors, principally Tecnol. Ana-go’s marketing strategy has focused almost exclusively on U.S. hospitals, although in recent years Anago has begun to experience some- success in international markets. Anago had about $19 million in sales for the fiscal year ended November 1991.

Tecnol is a publicly held corporation, incorporated in 1976, with sales of approximately $55 million in 1991. Tecnol is the industry leader in surgical masks, isolation masks, and insulated ice packs, capturing the largest market share of each product' as sold to U.S. hospitals. Tecnol’s marketing strategy, for the most part, is broader and more developed than Anago’s; Tecnol *516 sells a broader range of products to a wider array of users. Tecnol has sought to enhance its sales to dentists and industrial users, not simply hospitals. Additionally, international sales of its products comprised approximately 20 percent of its gross sales in 1991.

The events which brought the two companies before this Court began sometime in Fall 1991 when Tecnol began discussions with two major Anago shareholders, Joel Douglas Inman and Paul Shepard, about purchasing their stock. Inman was a co-founder of the company and former chairman of the board. He owned 11.4 percent of Anago’s outstanding common stock, and was the third largest common shareholder. Shepard, also a former chairman of the board, owned 14.7 percent of Anago’s outstanding common stock, and was Anago’s second largest shareholder. Tecnol’s negotiations with Inman and Shepard culminated in an agreement to purchase all of their shares.

With Inman’s help, Tecnol contacted representatives of Anago’s four preferred shareholders and a select number of common shareholders in late 1991 and early 1992. The four preferred shareholders were sophisticated venture capital groups, Anago Partners, L.P., LKCM Investment Partnership, Capital Southwest Venture Corporation, and Cumberland Capital Corporation. After extensive negotiations, Tecnol purchased 100 percent of Anago’s preferred stock in late January 1992. Tec-nol also contacted about ten common shareholders regarding purchase of their stock, a number of whom have agreed to sell.

At present, Tecnol owns a substantial portion, though not a majority, of Anago’s stock. Anago’s motion for preliminary injunction is designed to prevent any further acquisition of Anago stock by Tecnol. In the Fifth Circuit, a preliminary injunction will issue only when the movant has established the following: (1) a substantial likelihood of success on the merits; (2) a substantial threat that the movant will suffer irreparable injury if the injunction is not issued; (3) the threatened injury to the movant outweighs any damage the injunction might cause to the opponent; and (4) that the injunction will not disserve the public interest. Gearhart Indus., Inc. v. Smith Int’l, Inc., 741 F.2d 707 (5th Cir.1984); Canal Authority of State of Florida v. Callaway, 489 F.2d 567, 573 (5th Cir.1974).

II. SECURITIES CLAIM

Anago asserts that Tecnol violated Section 14(e) of the Williams Act by not disclosing to various Anago shareholders information regarding the true value of Anago stock. Specifically, Anago asserts that Tecnol obtained confidential inside information from Inman and Shepard about Anago, and did not disclose that information when negotiating with Anago shareholders. Without that information, says Anago, the shareholders could not make an informed decision of whether to sell.

Section 14(e) makes it unlawful to include in a tender offer any untrue statement of a material fact or to omit any material fact necessary to make statements not misleading. Section 14(e), however, is not triggered unless the stock transactions at issue constituted a “tender offer”; privately negotiated transactions are outside the province of Section 14. See, e.g., Wellman v. Dickinson, 475 F.Supp. 783 (S.D.N.Y.1979), aff'd on other grounds, 682 F.2d 355 (2d Cir.1982), cert. denied, 460 U.S. 1069, 103 S.Ct. 1522, 75 L.Ed.2d 946 (1983).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Clearfield Bank & Trust Co. v. Omega Financial Corp.
65 F. Supp. 2d 325 (W.D. Pennsylvania, 1999)
William Hall v. Don Shaw
Court of Appeals of Tennessee, 1999
Anago, Inc. v. Tecnol Medical Products, Inc.
976 F.2d 248 (Fifth Circuit, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
792 F. Supp. 514, 1991 U.S. Dist. LEXIS 20114, 1992 WL 89167, Counsel Stack Legal Research, https://law.counselstack.com/opinion/anago-inc-v-tecnol-medical-products-inc-txnd-1992.